We await further updates then ,
Further updates will be provided as information is released by the relevant agencies.
All clinical data to date on DMX-200 demonstrates an exceptionally strong safety profile, with no serious adverse events related to the drug reported, and that the DMX-200 clinical benefit has outweighed any risks to date.
The positive signals suggest that treatment with DMX-200 may indeed result in clinically meaningful improvements in kidney function in FSGS patients.
I'm full to the gunnels...
Hope you have a relaxing weekend with friends and family , NZT
We await further updates then , Further updates will be provided...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.5¢ |
Change
-0.015(3.33%) |
Mkt cap ! $239.5M | |||
| Open | High | Low | Value | Volume |
| 43.5¢ | 43.8¢ | 42.0¢ | $988.7K | 2.301M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 43.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.5¢ | 17061 | 1 |
View Market Depth
| Last trade - 16.10pm 04/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |